Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5523887 | Best Practice & Research Clinical Haematology | 2016 | 5 Pages |
Abstract
A high relapse rate for patients with acute myeloid leukemia (AML) is still a major barrier to the long-term survival of these patients. Nevertheless, considerable progress has been made both in the biology and therapy of the disease. Specifically, progress has been made in the areas of integrated genomic analysis for prognosis, the widening application of minimal residual disease (MRD) monitoring in clinical practice, the development of new agents, and the increasing use of drugs, such as IDH and FLT3 inhibitors, as a bridge to transplant. Continued progress and inquiry into these and other areas are essential to improve the survival outcome for adult patients with AML.
Keywords
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Jacob M. Rowe,